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Abstract Introduction: It has been suggested that neu-
ropsychiatric events during use of mefloquine are more
common in females than in males and are partly ex-
plained by the psychological stress of travelling. There-
fore, we investigated neuropsychiatric events in females
and males on mefloquine in the 3-week prophylactic
period that precedes travelling. Furthermore, we inves-
tigated whether first-time users had a higher risk of
neuropsychiatric adverse events than subjects with a
history of mefloquine use.
Methods: We enrolled all patients who visited a Travel
Clinic for mefloquine prophylaxis during the period 1
May 1999 to 7 March 2000. Each patient was followed
from baseline (prior to starting mefloquine) up to
3 weeks after the start of mefloquine but before travel-
ling. We asked patients to register any adverse event in a
diary and measured the intra-individual change in scores
on the Dutch Shortened Profile Of Mood States (POMS)
at baseline and at the end of follow-up.
Results: The final cohort consisted of 179 subjects with
a mean age of 3 years. Females reported adverse events
more frequently than males (P=0.005). Overall, we
observed a small but significant increase in the score on
the domain fatigue [0.74 points, 95% confidence interval
(CI) 0.18, 1.30]. The effect was exclusively present in
females and not in males. First-time users of mefloquine
increased 2.81 points (95% CI 0.70, 4.92) on the total
score of the POMS, and among those, women showed
the largest increase of 4.58 points (95% CI 0.74, 8.43).
Conclusion: The use of mefloquine was associated with
neuropsychiatric adverse effects. Females encountered
neuropsychiatric effects more frequently than males,
which could be confirmed by validated psychological
tests. Neuropsychiatric effects were more common in
first-time users than in individuals who had used
mefloquine before.
Keywords Neuropsychiatric events Æ Prophylaxis Æ
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Introduction
In theNetherlands,mefloquine is currently the first choice
for malaria prophylaxis in travellers staying more than
7 nights in areas with chloroquine-resistant falciparum
malaria [1]. Mefloquine is a quinoline derivative that is
used in a dose of 250 mg weekly. In order to obtain ade-
quate prophylactic blood levels and to detect adverse
effects at an early stage, mefloquine is usually started
3 weeks before travelling. During the last years, case
reports on neuropsychiatric adverse events and subse-
quent media attention have influenced the public opinion
on the use of mefloquine [2, 3, 4, 5]. Two types of neuro-
psychiatric adverse events have been attributed to the use
of mefloquine: (1) a sensation of dizziness, dysphoria,
light-headedness and difficulty in concentrating which
occurs within 6 h after intake and usually resolves during
the following days; (2) acute psychosis with agitation or
depression, occurring in the second week after starting
prophylaxis [6]. In a previous study, we found that women
in particular developed insomnia onmefloquine [7]. Other
studies also found more neuropsychiatric effects in
women than in men [8, 9]. Several studies, however, did
not take into account the stress of travelling itself.
Some authors have suggested that physiological and
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psychological stress of intercontinental travel may con-
found the association between mefloquine and neuro-
psychiatric adverse events [8, 10, 11]. Therefore, we
further explored the difference between neuropsychiatric
adverse effects in males and females onmefloquine during
the 3-week prophylactic period that precedes travelling.
Furthermore, we investigatedwhether first-time users had
a higher risk of neuropsychiatric adverse events than
subjects with a history of mefloquine use.
Methods
We conducted a prospective cohort study in the Travel Clinic of the
Havenziekenhuis and Institute for Tropical Diseases Rotterdam,
the Netherlands. The study was approved by the local medical
ethics committee.
Cohort definition
Our potential study population consisted of all persons who visited
the travel clinic for malaria prophylaxis during the study period that
started 1May 1999 and ended 7March 2000. Subjects were recruited
at the first visit (baseline), during which they were asked for written
informed consent. Follow-up ended at a scheduled visit 2 weeks or
3 weeks after starting prophylaxis but always prior to departure to
the tropics. We included all subjects who received a prescription for
mefloquine and excluded all persons who had either one or more
contraindications for mefloquine (history of epilepsy, psychosis or
depression, known allergy or sensitivity to mefloquine, concurrent
use of cardiovascular medication). Subsequently, we excluded
subjects who had used mefloquine in the preceding 2 months and
those who had other risk factors for concentration impairment (e.g.
use of opioids, hypnotics or tranquillisers during the 2 weeks prior to
testing, use of alcohol 4 h prior to testing).
Outcomes
We studied two different outcomes. The first outcome measure was
the intra-individual change in score on the Dutch Shortened Profile
Of Mood States (POMS). The POMS is a validated questionnaire
for the measurement of subjective mood. The POMS contains 32
questions and is designed to measure feelings in five domains:
tension, depression, anger, fatigue and vigour. The answers are
graded on a five-point scale ranging from ‘‘not at all’’ (scale 0) to
‘‘extremely’’ (scale 4) [12]. The total mood disturbance (TMD) is a
composite overall score, which can be calculated by summing the
raw scores across the four categories (tension, anger, fatigue and
depression) and subtracting vigour. The calculated total score
ranges from –20 to 108, and an increase in TMD means an increase
of mood disturbance. For every subject, the reference score was
assessed before start of therapy (baseline date) and the index score
after the second or third tablet of mefloquine (index date), shortly
before travelling.
The second outcome was the occurrence of neuropsychiatric
adverse events. All subjects were asked to register all adverse events
that were encountered during the first 3 weeks of use of mefloquine
in a diary.
Exposure to mefloquine
Previous exposure to mefloquine was assessed using a questionnaire
at baseline. Use of mefloquine during the study period was assessed
by means of a diary sheet on which subjects were asked to fill out
dose and dosing times from the start until the end of follow-up.
Compliance with use of mefloquine was assessed on the basis of
diary recordings.
Covariates
Data were gathered at baseline on demographics, weight, height,
education, travel destination and chronic co-morbidity. Fur-
thermore, data on risk factors, which may vary over time and
which are potentially related to the outcomes on the POMS
scales, were collected at the start and at the end of follow-up.
These included the use of alcohol, coffee, co-medication and
illicit drugs.
Analysis
We calculated that to demonstrate a standardised difference in
TMD of 0.5 with a power of 0.8 at a two-sided significance level of
0.05 and assuming a participation rate of 80%, would require ap-
proximately 150 individuals. The primary comparison comprised
the intra-individual change (delta) in the scores on the POMS do-
mains between baseline and at the end of follow-up. Univariate
analyses of continuous variables were conducted by means of
paired t-tests. In order to study the association between time-
independent covariates such as co-morbidity, age and gender and
the change in scores we used linear-regression models. In a second
step, we identified through stratification whether the intra-indi-
vidual effects were associated with previous use of mefloquine and
with the self-reported neuropsychiatric adverse events. In order to
study the association between time-dependent covariates such as
use of coffee and medication and the change in scores, we used the
general linear model for repeated measurements. All tests were two-
sided with rejection of the null hypothesis at a P value less than
0.05. The risk of neuropsychiatric adverse events as reported by the
subjects within the first weeks of use were calculated for persons
who completed follow-up (per protocol analysis) and for all per-
sons who were initially recruited. Furthermore, to check internal
consistency we compared the change in scores on the POMS in
subjects with and without self-reported adverse events.
Results
We enrolled a total of 200 subjects in the cohort, of whom
179 (89.5%) completed follow-up. Reasons for loss to
follow-up were: withdrawal of informed consent (n=12),
cessation of mefloquine because of neuropsychiatric ad-
verse effects (n=5), cancelling of the trip (n=3) and
moving to another part of the Netherlands (n=1). Of the
21 subjects dropping out, 9 (42.9%) were female. Com-
parisonof the scores on thePOMSatbaseline showed that
dropouts had significantly higher scores on the domains
tension and depression than participants.
Hence, the final cohort for whom we obtained scores
on the POMS on both occasions consisted of 179 sub-
jects with a mean age of 39 years. General characteristics
of the study population are presented in Table 1. Only
9% of subjects were experiencing medical complaints at
the time of enrolment but these were non-serious. No
differences were observed between males and females
regarding age, highest education, marital status, number
of smokers and presence of medical complaints at
baseline. The travel destination was predominantly
Africa (67.4%) and the reason for travelling tourism
(Table 1). The majority of the study population planned
their travel together with others (88.8%). We observed
no differences between males and females regarding the
travel characteristics. In our cohort, 70 subjects (39.3%)
had used mefloquine before, and 21 subjects (30.4%)
442
had encountered non-serious adverse events during
previous use of mefloquine. Upon prompting by ques-
tionnaire, 58 subjects (21 males and 37 females) reported
neuropsychiatric adverse events attributed to the use of
mefloquine (cumulative incidence for per protocol
analysis: 32.4%; idem for intention-to-treat analysis:
31.5%). Females reported adverse events more fre-
quently than males (P=0.002). The most frequently re-
ported adverse events comprised insomnia (n=23),
headache (n=15), fatigue (n=14), dizziness (n=13),
abnormal dreams/nightmares (n=12) and anxiety/de-
pression/emotional lability (n=9). The risk of at least
one neuropsychiatric adverse event was 44.6% for fe-
males [95% confidence interval (CI) 34.5%, 54.7%] and
22.1% for males (95% CI 13.8%, 30.4%). The risk of
neuropsychiatric adverse events during the first 3 weeks
of first-time use of mefloquine was 38.0% (95% CI
28.8%, 47.1%) and in those with a history of use 24.3%
(95% CI 14.2%, 34.3%). With respect to the POMS, we
observed small increases during follow-up on all do-
mains but the change was only significant on the domain
fatigue and TMD for females (Table 2). No changes
were observed in males. Adjustment for time-dependent
covariates did not affect the results. Stratification for
history of use of mefloquine showed that the TMD and
the scores on the domains anger and vigour differed
between first-time users and those who had used me-
Table 1. General characteris-
tics of the study population Total (n=179) Males (n=95) Females (n=84)
Average age in years (range) 39 (11–76) 40 (11–68) 37 (15–76)
BMI (kg/m2, range) 24.1 (15.8–35.8) 24.9 (15.8–35.8) 23.2 (17.0–33.3)
Highest educationa
Primary/vocational education 16 (9.1%) 11 (11.8%) 5 (6.0%)
Secondary/vocational education 79 (44.9%) 43 (46.2%) 36 (43.4%)
College/university 81 (46.0%) 39 (41.9%) 42 (50.6%)
Marital statusa
Unmarried 70 (40.2%) 39 (42.4%) 31 (37.8%)
Married/living together 100 (57.5%) 50 (54.3%) 50 (61.0%)
Divorced 4 (2.3%) 3 (3.3%) 1 (1.2%)
Smokinga
Yes 44 (24.7%) 24 (25.3%) 20 (24.1%)
No 134 (75.3%) 71 (74.7%) 63 (75.9%)
Medical complaintsa
Yes 16 (9.0%) 7 (7.4%) 9 (11.0%)
No 161 (91.0%) 88 (92.6%) 73 (89.0%)
Destination of travela
Africa 120 (67.4%) 65 (68.4%) 55 (66.3%)
Asia 48 (27.0%) 25 26.3%) 23 (27.7%)
South America 8 (4.5%) 4 (4.2%) 4 (4.8%)
Combined 2 (1.1%) 1 (1.1%) 1 (1.2%)
Reason for travellinga
Business 10 (5.7%) 5 (5.4%) 5 (6.0%)
Tourist 149 (85.1%) 77 (83.7%) 72 (86.7%)
Both 16 (9.1%) 10 (10.9%) 6 (7.2%)
Travelling alonea
Yes 20 (11.2%) 10 (10.5%) 10 (12.0%)
No 158 (88.8%) 85 (89.5%) 73 (88.0%)
aNumbers do not add up to total since some subjects did not answer all questions
BMI body mass index
Table 2. Changes in scores on the profile of mood states (POMS)
Score Mean
difference
95% CI P value
t0 t1 t1–t0
Total population
Tension 1.86 1.96 0.10 –0.31, 0.51 0.629
Depression 0.53 0.86 0.33 –0.02, 0.67 0.061
Anger 1.54 1.64 0.10 –0.48, 0.68 0.734
Fatigue 2.50 3.24 0.74 0.18, 1.30 0.010*
Vigour 11.33 11.31 –0.02 –0.60, 0.56 0.940
TMD –4.90 –3.60 1.30 –0.30, 2.89 0.111
Males
Tension 1.72 1.80 0.08 –0.44, 0.61 0.751
Depression 0.33 0.44 0.11 –0.11, 0.34 0.303
Anger 1.79 1.39 –0.40 –1.13, 0.33 0.282
Fatigue 2.08 2.48 0.40 –0.28, 1.08 0.246
Vigour 11.85 12.26 0.41 –0.33, 1.16 0.277
TMD –5.94 –6.15 –0.21 –1.85, 1.43 0.800
Females
Tension 2.02 2.14 0.12 –0.53, 0.77 0.717
Depression 0.76 1.33 0.57 –0.12, 1.27 0.106
Anger 1.26 1.93 0.67 –0.26, 1.59 0.155
Fatigue 2.96 4.09 1.13 0.21, 2.05 0.017*
Vigour 10.74 10.22 –0.52 –1.43, 0.40 0.270
TMD –3.73 –0.73 3.00 0.15, 5.85 0.039*
*Statistically significant differences
TMD (total mood disturbance) = tension + depression + anger
+ fatigue – vigour. CI confidence interval
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floquine before (Table 3). This difference was due to the
significant increase on these domains among first-time
users, whereas no changes were observed among previ-
ous users of mefloquine (Table 3). These changes were
only statistically significant in female first-time users.
Comparison of the change in score on the POMS be-
tween subjects with and without reported adverse events
showed that within subjects reporting neuropsychiatric
adverse events the scores on the domains depression and
fatigue, as well as the TMD (4.59 points, 95% CI 0.92,
8.25) increased significantly (Table 4). Between the two
groups significant differences were observed on the do-
mains anger and vigour as well as the TMD.
Discussion
In this study, we found thatmild neuropsychiatric adverse
events during the first weeks of prophylactic use of
mefloquine are common. This endorses the policy in some
countries to start mefloquine prophylaxis at least 3 weeks
prior to departure. If adverse events develop, they usually
appear early at a time that the patient can still switch to
another antimalarial. Mefloquine has acetylcholinester-
ase-inhibiting properties, and stereospecific inhibition of
acetylcholinesterase has been reported [13, 14]. It is
known that acetylcholinesterase inhibitors are able to
affect the central nervous system resulting in anxiety,
restlessness, disrupted concentration and memory, con-
fusion, sleep disturbances and convulsions [15]. Hence,
the adverse-reaction profile of mefloquine is compatible
with its pharmacological activity. The high short-term
risk of encountering neuropsychiatric events of approxi-
mately 32% among the population of young and healthy
travellers who used mefloquine as malaria prophylaxis
during the run-in period of 3 weeks is higher than the
previously reported incidences of 11.2% [8], 17.4% [11]
and 18.7% [16]. It is possible that the fact thatwe explicitly
Table 3. Comparison of the scores on the profile of mood states (POMS) between subjects with and without previous use of mefloquine
Subjects with previous use (n=70) Subjects without previous use (n=108) Subjects with vs without
Mean difference (95% CI) P value Mean difference (95% CI) P value Previous use P value
Total
Tension 0.17 (–0.54, 0.89) 0.634 0.06 (–0.45, 0.56) 0.828 0.787
Depression –0.06 (–0.39, 0.28) 0.734 0.58 (0.05, 1.11) 0.031* 0.075
Anger –0.77 (–1.78, 0.24) 0.131 0.67 (–0.04, 1.37) 0.063 0.028*
Fatigue 0.41 (–0.44, 1.27) 0.339 0.96 (0.21, 1.71) 0.012* 0.349
Vigour 0.77 (–0.14, 1.68) 0.096 –0.54 (–1.30, 0.22) 0.164 0.031*
TMD –1.01 (–3.44, 1.41) 0.407 2.81 (0.70, 4.92) 0.010* 0.021*
Males
Tension 0.10 (–0.93, 1.13) 0.846 0.07 (–0.47, 0.62) 0.790 0.292
Depression 0.05 (–0.18, 0.28) 0.660 0.16 (–0.19, 0.52) 0.355 0.619
Anger –1.12 (–2.44, 0.19) 0.091 0.13 (–0.72, 0.97) 0.764 0.960
Fatigue –0.03 (–1.16, 1.12) 0.965 0.71 (–0.15, 1.57) 0.104 0.182
Vigour 1.00 (–0.04, 2.04) 0.060 –0.02 (–1.07, 1.03) 0.972 0.094
TMD –2.00 (–4.93, 0.93) 0.175 1.09 (–0.79, 2.97) 0.251 0.065
Females
Tension 0.27 (–0.75, 1.28) 0.595 0.04 (–0.85, 0.92) 0.932 0.818
Depression –0.20 (–0.94, 0.54) 0.586 1.02 (–0.0003, 2.04) 0.050 0.099
Anger –0.30 (–1.94, 1.34) 0.712 1.23 (0.08, 2.37) 0.036* 0.742
Fatigue 1.00 (–0.37, 2.37) 0.146 1.23 (–0.04, 2.49) 0.058 0.113
Vigour 0.47 (–1.21, 2.15) 0.574 –1.08 (–2.19, 0.04) 0.058 0.120
TMD 0.30 (–3.95, 4.55) 0.886 4.58 (0.74, 8.43) 0.021* 0.156
*Statistically significant differences
TMD (total mood disturbance) = tension + depression + anger + fatigue – vigour. CI confidence interval
Table 4. Comparison of the
scores on the profile of mood
states (POMS) between subjects
with and without neuropsychi-
atric adverse events (AEs)
Subjects with AEs (n=58) Subjects without AEs (n=120) P valuea
Mean difference (95% CI) P value Mean difference (95% CI) P value
Tension 0.26 (–0.64, 1.16) 0.567 0.03 (–0.41, 0.46) 0.911 0.787
Depression 0.97 (0.16, 1.77) 0.019* 0.03 (–0.31, 0.36) 0.883 0.075
Anger 0.97 (–0.33, 2.26) 0.142 –0.32 (0.92, 0.29) 0.300 0.018*
Fatigue 1.76 (0.46, 3.06) 0.009* 0.26 (–0.29, 0.80) 0.350 0.349
Vigour –0.64 (–1.67, 0.39) 0.220 0.28 (–0.44, 0.99) 0.449 0.031*
TMD 4.59 (0.92, 8.25) 0.015* –0.28 (–1.84, 1.27) 0.719 0.021*
*Statistically significant differences
aSubjects with vs without AEs
CI confidence interval
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askedpatients to report potential adverse effectsmayhave
caused a bias towards over-reporting. This bias could not
be avoided as it is currently state of the art to treat people
with a prophylactic dose of mefloquine for 3 weeks pre-
ceding travelling in order to be able to change treatment in
case of neuropsychiatric adverse events [1]. In case of such
events, people are advised to come back for alternative
treatment. Nevertheless, the concurrent abnormalities on
the POMS questionnaire confirm that these events are
common and the differences between males and females
and between first-time and regular users of mefloquine
suggest a difference in vulnerability. A possible explana-
tion for differences between males and females might be
that females are more aware of neuropsychiatric distur-
bances thanmales and communicate this more easily than
males. Another explanation for differences betweenmales
and females might be a gender-specific difference in bio-
availability ormetabolism ofmefloquine, although such a
difference was not demonstrated in one small study [17].
The fact that individuals with a history of mefloquine use
did not demonstrate neuropsychiatric abnormalities on
the POMS may be explained by the phenomenon of ‘de-
pletion of susceptibles’. This means that persons who
encounter adverse events will not use the drug again
whereas those without adverse events will use the drug
again during their future travels.
Some authors have suggested that the physiological
and psychological stress of intercontinental travel may
be of importance for mefloquine-associated neuropsy-
chiatric adverse events [8, 10, 11]. In this study, we tried
to eliminate the effects of travel by assessing the adverse
effects after the third tablet of mefloquine at the time
that all subjects were still at home. Our results show that
neuropsychiatric adverse events occur within 3 weeks
after starting mefloquine and occur independently of
intercontinental travel.
Before drawing conclusions we need to emphasise
some limitations that may affect the internal and external
validity of our study. Firstly, we compared changeswithin
subjects who were all taking a prophylactic dose of me-
floquine. Although this allowed for elimination of con-
founding by subject characteristics, all individuals were
aware of the fact that they received active treatment. We
could not include a placebo group for ethical consider-
ations nor an actively treated comparator group since the
alternative chemoprophylaxis is started on the day of
departure. Therefore, we may have overestimated the ef-
fect on the POMS. Secondly, the external validity of our
studymay have been affected by the selection of our study
population. The selection of the cohort is based on the
prescription of mefloquine to persons planning to make a
trip to a tropical area forwhichmefloquine is advised. The
choice of chemoprophylaxis is based on the absence of
contraindications for the drug and the tropical area vis-
ited. This leads to a selection of a relatively healthy cohort
formed by first-time users (with no known contraindica-
tions for the drug) and travellerswhohadusedmefloquine
before but who did not encounter serious adverse events.
This shows that previous use of mefloquine should be
taken into account when generalising the effects to the
population of users of mefloquine for chemoprophylaxis.
In conclusion, mefloquine-associated neuropsychiat-
ric adverse effects were demonstrated during the run-in
period of 3 weeks of the use of a prophylactic dose of
250 mg weekly. These effects were most common in
women and first-time users. Future studies should
further explore other risk factors for neuropsychiatric
adverse events.
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